INDIANAPOLIS (dpa-AFX) – Eli Lilly and Company (LLY) and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. The company’s lead asset, bimagrumab, is being advanced in the BELIEVE Phase…Read More
Eli Lilly To Acquire Versanis Bio
